Adjuvant TACE combined with tislelizumab in patients with resected hepatocellular carcinoma at high risk of recurrence: An open-label, multicenter, phase II trial

被引：0
|
作者：
Ma, T. [1 ]
Wen, L. [1 ]
Zhang, J. [2 ]
Zhang, Z. [3 ]
Zeng, Y. [4 ]
Wang, Y. [5 ]
Zheng, J. [6 ]
Liang, T. [1 ]
机构：
[1] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Hepatobiliary & Pancreat Surg, Hangzhou, Peoples R China
[2] China Med Univ, Affiliated Hosp 1, Clin Med, Shenyang, Peoples R China
[3] Shandong Univ, Qilu Hosp, Dept Hepatobiliary Surg, Jinan, Peoples R China
[4] Fujian Med Univ, Mengchao Hepatobiliary Hosp, Dept Hepatobiliary & Pancreat Surg, Fuzhou, Peoples R China
[5] Tianjin Third Cent Hosp, Dept Hepatobiliary Surg, Tianjin, Peoples R China
[6] Hainan Gen Hosp, Dept Hepatobiliary & Pancreat Surg, Haikou, Hainan, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.10.259
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
239P
引用
收藏
页码：S1494 / S1494
页数：1
相关论文
共 50 条
  • [31] An open-label, phase II trial of cabozantinib for advanced adrenocortical carcinoma
    Campbell, M. T.
    Jimenez, C.
    Long, J. P.
    Varghese, J.
    Shah, A.
    Zhang, M.
    Tamsen, G.
    Habra, M. A.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S545 - S545
  • [32] Sitravatinib plus tislelizumab for metastatic uveal melanoma with liver metastasis: The open-label, multicenter, phase II GEM-2101 trial
    de Carpio Huerta, L. P.
    Espinosa, E.
    de la Cruz Merino, L.
    Berrocal-Jaime, A.
    Piulats, J. M.
    ANNALS OF ONCOLOGY, 2024, 35 : S716 - S716
  • [33] Phase II study of transhepatic artery chemoembolization (TACE) combined with tislelizumab (TIS) and lenvatinib (LEN) in patients with unresectable hepatocellular carcinoma(uHCC)
    Nong, X.
    Xie, J-L.
    Zhang, Y-M.
    Liang, J-C.
    Pan, Z-L.
    Zhang, Z-M.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S871 - S871
  • [34] Hepatic arterial infusion chemotherapy sequential transarterial embolization combined with lenvatinib and tislelizumab in patients with high-risk unresectable hepatocellular carcinoma: A phase II trial
    Zhong, J-H.
    Deng, Z.
    Qi, L-N.
    Chen, Z-S.
    Zhang, Z-M.
    Xiang, B.
    Ma, L.
    ANNALS OF ONCOLOGY, 2024, 35 : S1484 - S1484
  • [35] Neoadjuvant tislelizumab combined with lenvatinib plus transcatheter arterial chemoembolization in resectable hepatocellular carcinoma with high-risk of recurrence: A prospective, single-arm, phase II trial
    Chen, Zhiyu
    Zhang, Leida
    Zhang, Hui
    Gong, Yi
    Feng, Kai
    Ma, Kuansheng
    Bi, Huaqiang
    Xia, Feng
    Dai, Haisu
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [36] An open-label, multicenter phase II trial of sunitinib for patients with chemorefractory metastatic gastric cancer.
    Moehler, M. H.
    Hartmann, J. T.
    Lordick, F.
    Al-Batran, S.
    Reimer, P.
    Trarbach, T.
    Ebert, M. P.
    Daum, S.
    Weihrauch, M.
    Galle, P. R.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [37] A phase II, multicenter, open-label, randomized trial of pegfilgrastim for patients with alcohol-associated hepatitis
    Morgan, Timothy
    Asghar, Aliya
    Tayek, John
    Nguyen, Danh
    Fleischman, M. Wayne
    Donovan, John
    Alcorn, Joseph
    Chao, Daniel
    Stolz, Andrew
    JOURNAL OF HEPATOLOGY, 2022, 77 : S142 - S142
  • [38] A phase II, multicenter, open-label, randomized trial of pegfilgrastim for patients with alcohol-associated hepatitis
    Tayek, John A.
    Stolz, Andrew A.
    Nguyen, Danh, V
    Fleischman, M. Wayne
    Donovan, John A.
    Alcorn, Joseph M.
    Chao, Daniel C-K
    Asghar, Aliya
    Morgan, Timothy R.
    ECLINICALMEDICINE, 2022, 54
  • [39] Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study
    Faivre, Sandrine
    Raymond, Eric
    Boucher, Eveline
    Douillard, Jean
    Lim, Ho Y.
    Kim, Jun S.
    Zappa, Magaly
    Lanzalone, Silvana
    Lin, Xun
    DePrimo, Samuel
    Harmon, Charles
    Ruiz-Garcia, Ana
    Lechuga, Maria J.
    Cheng, Ann Lii
    LANCET ONCOLOGY, 2009, 10 (08): : 794 - 800
  • [40] TACE plus sorafenib for the treatment of hepatocellular carcinoma: results of the multicenter, phase II SOCRATES trial
    Andreas Erhardt
    Frank Kolligs
    Matthias Dollinger
    Eckart Schott
    Hennig Wege
    Michael Bitzer
    Christiane Gog
    Frank Lammert
    Markus Schuchmann
    Clemens Walter
    Dirk Blondin
    Christian Ohmann
    Dieter Häussinger
    Cancer Chemotherapy and Pharmacology, 2014, 74 : 947 - 954
12345